The RNAi therapeutics developer increased its series C funding to $47m following a second tranche led by corporate joint venture CR-CP Life Sciences Fund.

US-based drug developer Sirnaomics completed a $47m series C round on Friday after securing a $22m extension led by corporate joint investment vehicle CR-CP Life Sciences Fund.

CR-CP Life Sciences, a $300m fund jointly manged by conglomerates China Resources Group and Charoen Pokphand Group, was joined in the second tranche by Rich Yield Capital, Rolling Boulder Investment and Legend Sky Investment.

The extension follows an initial $25m close in June 2018 that was led by Yuexiu New Industrial Investment with…